The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jul. 15, 2014
Filed:
Jun. 26, 2008
Gryssell María Rodríguez Martínez, Ciudad de la Habana, CU;
Lisel Viña Rodríguez, Ciudad de la Habana, CU;
Loany Calvo González, Ciudad de la Habana, CU;
Ariadna Cuevas Fiallo, Ciudad de la Habana, CU;
Ernesto Chico Véliz, Ciudad de la Habana, CU;
Agustín Bienvenido Lage Dávila, Ciudad de la Habana, CU;
Tania Crombet Ramos, Ciudad de la Habana, CU;
Airama Albisa Novo, Ciudad de la Habana, CU;
Gisela Maria González Marinello, Ciudad de la Habana, CU;
Gryssell María Rodríguez Martínez, Ciudad de la Habana, CU;
Lisel Viña Rodríguez, Ciudad de la Habana, CU;
Loany Calvo González, Ciudad de la Habana, CU;
Ariadna Cuevas Fiallo, Ciudad de la Habana, CU;
Ernesto Chico Véliz, Ciudad de la Habana, CU;
Agustín Bienvenido Lage Dávila, Ciudad de la Habana, CU;
Tania Crombet Ramos, Ciudad de la Habana, CU;
Airama Albisa Novo, Ciudad de la Habana, CU;
Gisela Maria González Marinello, Ciudad de la Habana, CU;
Centro de Inmunologia Molecular (CIM), Havana, CU;
Abstract
The present invention concerns the biotechnology sector and more specifically human healthcare. In particular, the present invention describes a vaccine composition for therapeutic use thereof on cancer patients. The vaccine composition described in the present invention has as active principle a chemical conjugate of human recombining Epidermic Growth Factor (hrEGF) and are combining protein P64k. In addition, specific conditions are described for performing a conjugation reaction which produces said chemical conjugate in a controlled and reproducible manner. In another embodiment, the present invention concerns a method for purification of the chemical conjugate which not only provides greater purity for the therapeutic composition, but surprisingly increases the immunogenic activity causing significant increases in the anti-EGF antibody titers in humans. In addition, the present invention provides the methodology for producing a vaccine preparation with more than one type of dose presentation (total milligrams of conjugates/vial). This versatility in the presentation of the vaccine preparation enables the immunization dose per patient to be increased, but without involving an increase in immunization frequency and/or the number of immunization sites. The present invention involves a healthcare method for producing the vaccine for cancer therapy, administered by parenteral means.